Adaptive Biotechnologies Other Cashflows From Investing Activities Over Time
| ADPT Stock | USD 6.44 0.05 0.78% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Adaptive Biotechnologies Performance and Adaptive Biotechnologies Correlation. Adaptive |
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Revenue Per Share 1.211 | Quarterly Revenue Growth 0.225 | Return On Assets (0.16) | Return On Equity (0.67) |
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptive Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Cashflows From Investing Activities Analysis
Compare Adaptive Biotechnologies and related stocks such as Verve Therapeutics, Beam Therapeutics, and Caribou Biosciences Other Cashflows From Investing Activities Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BEAM | (83.8 M) | (83.8 M) | (83.8 M) | (83.8 M) | (83.8 M) | (83.8 M) | (83.8 M) | (83.8 M) | (83.8 M) | (83.8 M) | (83.8 M) | (248 M) | (412.4 M) | (371.1 M) | (389.7 M) |
| CRBU | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | (1000 K) | (600 K) | (540 K) | (567 K) |
| SANA | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (228.7 K) | (4.6 M) | 231.4 K | 192 K | 201.6 K |
| RPRX | 936 K | (258.8 M) | (258.8 M) | (258.8 M) | (258.8 M) | (258.8 M) | (258.8 M) | (258.8 M) | (258.8 M) | (258.8 M) | 334.8 M | (37.8 M) | 123.4 M | 29.4 M | 30.9 M |
| HEPA | (495.6 K) | (495.6 K) | (495.6 K) | (495.6 K) | (495.6 K) | (495.6 K) | 900 | 900 | 900 | 2.2 K | 2.2 K | 2.3 K | 2.3 K | 2.6 K | 2.7 K |
| KRYS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (8.1 M) | 1.4 M | 100 M | 100 M | 100 M | 115 M | 120.8 M |
| ENVB | (44.14) | (44.14) | (44.14) | (44.14) | (44.14) | (44.14) | (44.14) | (44.14) | (44.14) | (44.14) | (44.14) | (675) | (958 K) | 16.8 K | 17.7 K |
| ELEV | (44.3 K) | (44.3 K) | (44.3 K) | (44.3 K) | (44.3 K) | (44.3 K) | (44.3 K) | (44.3 K) | (44.3 K) | (44.3 K) | (44.3 K) | (44.3 K) | (44.3 K) | (39.9 K) | (41.9 K) |
| ZURA | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (7.2 M) | (7.6 M) |
| LEGN | (75.3 M) | (75.3 M) | (75.3 M) | (75.3 M) | (75.3 M) | (75.3 M) | (75.3 M) | (75.3 M) | (75.3 M) | 50 M | (4 M) | (3.2 M) | (14.7 M) | (91.7 M) | (87.1 M) |
| VIR | 180 K | 180 K | 180 K | 180 K | 180 K | 180 K | 180 K | 180 K | 180 K | 180 K | 180 K | (140.8 M) | (1.1 B) | (1 B) | (962.3 M) |
| APLS | (311.6 M) | (311.6 M) | (311.6 M) | (311.6 M) | (311.6 M) | (311.6 M) | (311.6 M) | (311.6 M) | (311.6 M) | (311.6 M) | (311.6 M) | 248.7 M | 61.4 M | 99 K | 104 K |
Adaptive Biotechnologies and related stocks such as Verve Therapeutics, Beam Therapeutics, and Caribou Biosciences Other Cashflows From Investing Activities description
My Equities
My Current Equities and Potential Positions
| Adaptive Biotechnologies Corp | ADPT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Washington; U.S.A |
| Exchange | NASDAQ Exchange |
USD 6.44
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.